

WO0213820

Publication Title:

PHOTOSENSITIZING OINTMENT

Abstract:

Abstract of WO 0213820

(A1) Translate this text A system and a method using photodynamic therapy for the treatment of epithelial diseases are provided, wherein the photosensitizers used have enhanced selectivity for the affected region so that the treatment has less or no side effects. The selectivity is achieved by avoiding the systemic application of the photosensitizer as well as by using topical application of the photosensitizers with certain carries. Compositions of medical or cosmetic carriers like ointments, creams or lotions can be used as a carrier. Bacteriopheophorbides and its derivatives are preferred photosensitizers because of their abilities to penetrate the tissue and to distribute evenly, as well as their low threshold of photo toxicity. After the photo toxic sensitizer has been administered to the afflicted tissue, the tissue is irradiated with an appropriate radiation source, which can be sunlight or a radiation source emitting a defined wavelength like a diode laser. A deeper penetration of the radiation may be achieved by using longer wavelengths (700-800 nm), which are in the red part of the spectrum. The present invention provides a system that the photosensitizing agent can be topically applied easily and repeatedly, and thus especially useful for the therapy of a disease like psoriasis, where frequent and repeated treatments may be necessary. The present invention also provides a method of photodynamic therapy for epithelial diseases, which comprises the steps of: (a) applying topically a therapeutically effective amount of the photosensitizer like bacteriopheophorbide or a bacteriopheophorbide derivative at the treating area, which is afflicted by a epithelial disease or an infection, and (b) exposing the treated area of skin to radiation so that the radiation photoactivates the photosensitizer to produce a cytotoxic response in the afflicted area.

Courtesy of <http://v3.espacenet.com>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/13820 A1

- (51) International Patent Classification⁷: **A61K 31/40** (74) Agent: **SKUTNIK, Bolesh, J.**; CeramOptec Industries, Inc., 515 Shaker Road, East Longmeadow, MA 01028 (US).
- (21) International Application Number: PCT/US01/24964
- (22) International Filing Date: 9 August 2001 (09.08.2001) (81) Designated States (*national*): BR, CA, JP, KR.
- (25) Filing Language: English (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (26) Publication Language: English
- (30) Priority Data:
09/636,495 11 August 2000 (11.08.2000) US Published:
— with international search report
- (71) Applicant: **CERAMOPTEC INDUSTRIES, INC.** [US/US]; 515 Shaker Road, East Longmeadow, MA 01028 (US).
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
- (72) Inventor: **MOSER, Jörg, G.**; Lise-Meitner Strasse 33, 40591 Düsseldorf (DE).

(54) Title: PHOTSENSITIZING OINTMENT

(57) **Abstract:** A system and a method using photodynamic therapy for the treatment of epithelial diseases are provided, wherein the photosensitizers used have enhanced selectivity for the affected region so that the treatment has less or no side effects. The selectivity is achieved by avoiding the systemic application of the photosensitizer as well as by using topical application of the photosensitizers with certain carries. Compositions of medical or cosmetic carriers like ointments, creams or lotions can be used as a carrier. Bacteriopheophorbides and its derivatives are preferred photosensitizers because of their abilities to penetrate the tissue and to distribute evenly, as well as their low threshold of photo toxicity. After the photo toxic sensitizer has been administered to the afflicted tissue, the tissue is irradiated with an appropriate radiation source, which can be sunlight or a radiation source emitting a defined wavelength like a diode laser. A deeper penetration of the radiation may be achieved by using longer wavelengths (700-800 nm), which are in the red part of the spectrum. The present invention provides a system that the photosensitizing agent can be topically applied easily and repeatedly, and thus especially useful for the therapy of a disease like psoriasis, where frequent and repeated treatments may be necessary. The present invention also provides a method of photodynamic therapy for epithelial diseases, which comprises the steps of: (a) applying topically a therapeutically effective amount of the photosensitizer like bacteriopheophorbide or a bacteriopheophorbide derivative at the treating area, which is afflicted by a epithelial disease or an infection, and (b) exposing the treated area of skin to radiation so that the radiation photoactivates the photosensitizer to produce a cytotoxic response in the afflicted area.



WO 02/13820 A1

PHOTOSENSITIZING OINTMENT

Inventor: Jörg G. Moser

Assignee: CeramOptec Industries Inc.

Background of the Invention

1. Field of the invention

The present invention relates to photodynamic therapy of epithelial diseases, such as tumorous skin malignancies, psoriasis, and bacterial infections in wounds. The present invention also relates to topical application of bacteriopheophorbides in the course of photodynamic therapy of epithelial diseases.

2. Invention Disclosure Statement

The use of photosensitizers in treatment of hyperproliferative diseases such as tumours is well-known. The method, called photodynamic therapy (PDT), uses non-toxic, photosensitizing drugs in combination with non-hazardous light irradiation to destroy the malignant tissue or cells.

When cells containing photosensitizers are exposed to radiation of the respective absorbed wavelength that activates the photosensitizers, cytotoxicity is induced by intracellular formation of singlet oxygen, a short-lived, highly reactive state of the oxygen molecule. The photosensitizers used in PDT need to have characteristics of high affinity and selectivity for the malignant tissue as well as a high quantum yield for singlet oxygen production. Porphyrins have a high quantum yield to form an excited triplet state. The difference between the energies of the triplet state and their singlet ground state makes porphyrins good energy donors to transfer their energy to the ground state of oxygen to form the highly reactive singlet oxygen.

The wavelengths that are ideally used in PDT lie in the "photodynamic window" (650 – 850 nm) where biological chromophores in humans normally do not absorb. The minimum wavelength of 650 nm is given because of the absorption properties of biological chromophores, e.g. heme in hemoglobin, and light scatterers like melanin. The maximum wavelength is due to the energy transfer process from the sensitizer triplet to triplet oxygen to yield the reactive singlet oxygen. Since longer wavelengths penetrate deeper into the tissue, it is desirable that the photosensitizers

are activated by the longer wavelengths within the “photodynamic window” for the removal of a whole tumour.

Moreover, a photosensitizer should be characterised by a low “threshold dose,” which is the minimum energy dose at which a photosensitizer becomes photo
5 toxic. One of the photo toxic effects is a low power “overshot,” which is defined as the non-desirable activation of cell proliferation at low power densities.

The use of PDT has been described for therapies of inner organ tumours as well as skin malignancies. Epithelial diseases (epidermal and mucosal diseases) are a major health problem. Nearly everybody suffers from epithelial diseases several
10 times during his or her life. Examples of hyperproliferative epithelial diseases not only include cutaneous tumours (basal cell carcinoma, squamous cell carcinoma, melanoma), but also include psoriasis, virus-caused diseases (warts, herpes simplex, condylomata acuminata), premalignant and malignant diseases of the female genital tract (cervix, vagina, vulva), and premalignant and malignant diseases of mucosal
15 tissues (oral, bladder, rectal).

The most common skin disease is psoriasis. The causes of psoriasis probably lie in genetic factors which cannot be cured by the medical tools available today. Therefore, the therapy is reduced to control the symptoms. The treatment often has to be repeated during the lifetime of a patient. A variety of therapies currently used to
20 treat psoriasis include dialysis, chemotherapy (topical and systemic), and PDT (topical and systemic). Topical chemotherapy is probably the most widely used, employing agents such as retinoids, anthralin, corticosteroids, and antimetabolites. At present, the most severe cases of psoriasis are treated with systemic phototherapy, e.g. the use of oral methoxypsoralen and long-wave ultraviolet light (PUVA). Clinically,
25 PUVA has remained relatively effective for the majority of patients, and short-term side effects, such as widespread severe erythema, have been tolerable for the severely afflicted patients. The therapeutic mechanism of PUVA is proposed to be based on the binding of psoralens to the DNA of the afflicted cells. The binding leads to inhibition of DNA synthesis and consequent blocking of cell divisions. While the
30 inhibition of DNA synthesis may be the desirable outcome of psoriasis therapy, there are concerns that the direct changes in the DNA structure and function by PUVA may have potential carcinogenic and mutagenic effects. Thus, while methods employing

PUVA have shown some promises in the treatment of epithelial diseases so far, it is desirable to develop new therapeutic strategies that are equal or even more effective without undesirable side effects, such as erythema over unafflicted areas of a patient, and the potential carcinogenic effect of the treatments.

5 Also, the therapeutic potential of HPD for tumours was demonstrated, and several clinical trials using HPD photoirradiation therapy have been reported in patients with cutaneous or subcutaneous malignant tumours as well as for the treatment of psoriasis; in some countries such HDP based compounds have even received regulatory approval. However, the absorption maximum of HPD lies at
10 wavelengths where biological chromophores can absorb, and therefore the penetration depth of the irradiation is not sufficient to activate the photo toxic dye for a complete removal of the malignant tissue. Moreover, due to the high systemic doses necessary to achieve therapeutic levels of the photosensitizer at the tumour sites, high concentrations are detected in other, non-malignant organs. However,
15 Bacteriopheophorbide and its derivatives, e.g. 13-OH-bacteriopheophorbide, are dyes that meet the requirements for PDT much better than the dyes mentioned above. The maximum optical absorption of these compounds is located well into the longer wavelength part of the “photodynamic window” so that the irradiation used penetrates deep enough into the tissue for the removal of the whole tumour. The high photo
20 toxicity of the bacteriopheophorbides makes the therapy more efficient and thereby makes dosage reduction of the applied sensitizer possible. A reduced dosage of sensitizers reduces side effects of the therapy.

 Although bacteriopheophorbide and its derivatives are more efficient, they still have significant disadvantages when they are used systemically. One reason is that
25 the patient's entire skin is photosensitized. The advantage of PDT, compared with the commonly used chemotherapy or radiotherapy, is the selectivity for the treatment site through administration of irradiation only to a limited space, and this advantage cannot be easily achieved at the skin. Sun light reaching a patient's skin is sufficient to activate the photo toxicity of the sensitizer at least in the outer layers of the skin,
30 which causes widespread severe erythema. Therefore, the whole-body photosensitivity after systemic injection requires the patient to avoid direct sunlight or prolonged contact with bright artificial light for several weeks. Since many epithelial

diseases affect only small and superficial areas, it is unreasonable and inconvenient to treat such patients with a systemic medication and expose them to these side effects. One solution to this problem would be to develop a composition with a photoactive drug that is effective when applied topically. Topically applied drugs provide an ideal method of localizing the effects of the drug, since they need to be applied only to the afflicted tissue. However, many systemically active drugs are ineffective in topical formulations. It is especially hard for them to penetrate through the epidermis which is designed to protect the organism from foreign substances. The barrier function of the skin is achieved by its special cell types and assemblies. Keratinocyte is a type of cell that constitutes the epidermis, and corneocytes are linked by and embedded in lipid layers in the uppermost layer (stratum corneum) of the skin. Due to this structure, only hydrophobic substances, like bacteriopheophorbides, can penetrate effectively through the epidermis. This penetration is a prerequisite for the action of topically administered therapeutic agents.

The frequent occurrence of epithelial diseases makes an effective treatment without serious side effects necessary. The present invention is a possible answer to this high demand.

Brief Summary and Objects of the Invention

It is an object of the present invention to provide an effective therapeutic photodynamic method for the treatment of epithelial diseases, such as skin tumours, psoriasis, and infections of wounds.

It is another object of the present invention to provide a topical composition for the treatment of epithelial diseases, and at the meantime to avoid the serious side effects associating with the systemic administration of photosensitizers.

Yet another object of the present invention is to provide an improved photodynamic therapeutic method for the treatment of epithelial diseases by using improved photo therapeutic agents like bacteriopheophorbide and its derivatives.

Briefly stated, the present invention provides a system and a method using photodynamic therapy for the treatment of epithelial diseases, wherein the photosensitizers used have enhanced selectivity for the affected region so that the treatment has less or no side effects. The selectivity is achieved by avoiding the

systemic application of the photosensitizer as well as by using topical application of the photosensitizers with certain carriers. Compositions of medical or cosmetic carriers like ointments, creams or lotions can be used as a carrier.

5 Bacteriopheophorbide and its derivatives are preferred photosensitizers because of their abilities to penetrate the tissue and to distribute evenly, as well as their low threshold of photo toxicity. After the photo toxic sensitizer has been administered to the afflicted tissue, the tissue is irradiated with an appropriate radiation source, which can be sunlight or a radiation source emitting a defined wavelength like a diode laser. A deeper penetration of the radiation may be achieved by using longer wavelengths
10 (700-800 nm), which are in the red part of the spectrum. The present invention provides a system that the photosensitizing agent can be topically applied easily and repeatedly, and thus especially useful for the therapy of a disease like psoriasis, where frequent and repeated treatments may be necessary. The present invention also provide a method of photodynamic therapy for epithelial diseases, which comprises
15 the steps of: (a) applying topically a therapeutically effective amount of the photosensitizer like bacteriopheophorbide or a bacteriopheophorbide derivative at the treating area, which is afflicted by a epithelial disease or an infection, and (b) exposing the treated area of skin to radiation so that the radiation photoactivates the photosensitizer to produce a cytotoxic response in the afflicted area.

20 Detailed Description of Preferred Embodiments

For topical administration, a photosensitizer has to have such properties so that they can penetrate through the epidermis into the skin and to distribute evenly within the diseased tissue. Alternatively, certain additives have to fulfil these functions
25 while supporting the therapeutic action of the photosensitizers. The present invention is applicable to the treatment of epithelial diseases, such as hyperproliferative epithelial diseases, e.g. melanoma, psoriasis, and infections of wounds in animals (such as mammals, and particularly in humans). The present invention meets the special requirements for treating epithelial diseases, wherein the property of the
30 carrier used, the skin penetration depth of the drug, and the distribution of the drug are critical when the drug is topically administered.

The more hydrophilic the carrier is, the more efficient the penetration of the drug through the epidermis is. The penetration can be ameliorated by the use of penetration enhancers, which are frequently used in cosmetics and medicine. However, since such enhancers often cause irritation of the skin, e.g. by DMSO, their exclusion is preferred. Bacteriopheophorbides and its derivatives penetrate readily through the epidermis and distribute well within the skin without penetration enhancers. Therefore, they are especially preferred as therapeutic active photosensitizers in topical administrations. Moreover, Bacteriopheophorbides and its derivatives show lower threshold of photo toxicity compared to other photosensitizers. This is important for the topical application of the drug, since low concentrations are sufficient for the therapeutic action and removal of the abnormal tissues, e.g. the whole tumor. The photo toxicity can be used to destroy cancer cells while leaving healthy cells undamaged if the application of the photosensitizer and its radiation activation is strictly localized to the malignant tissue. Moreover, healthy cells have the capacity to regenerate when they are only slightly damaged by the photodynamic therapy.

The present invention is directed to treatment of epithelial diseases, such as infection of wounds, hyperproliferative diseases like tumours and psoriasis. Since these diseases are very common, there is a clear need for an efficient therapy. The use of PDT has been shown to be efficient in the treatment of tumour as well as psoriasis. However, the systemic administration of the photosensitizer used so far has the disadvantage of photosensitizing the patient's whole skin, so that the patient has to protect himself from light for several weeks to avoid the severe side effects of this whole-body photosensitization. The present invention provides a system using topical application instead of the systemic administration of the photosensitizer, so that the photo toxic drug is confined to the afflicted tissue.

The epithelial diseases, as used herein, mean conditions of the skin that are characterized by epidermal cell proliferation, incomplete cell differentiation, or other premalignant lesions. The topical compositions of the present invention may be used to treat hyperproliferative epithelial disease, including cutaneous malignancies which occur primarily to the skin (e.g. squamous cell carcinoma, basal cell carcinoma, melanoma), metastatic, non-nodal lesions of internal malignancies present on the skin,

psoriasis, viral diseases such as herpes simplex and warts, as well as bacterial infections.

The success of a therapy also depends on a drug's ability to penetrate through the epidermis and distribute evenly in deeper skin layers. When topically administered, bacteriopheophorbide and its derivatives in a suitable carrier meet these requirements very well. Fischer, 1922 demonstrates that bacteriopheophorbide and its derivatives, such as 13-OH-bacteriopheophorbide or metallo derivatives, are products from bacteriochlorophyll and are obtained by acid hydrolysis in acetone-sulfuric acid of the mother compound, bacteriochlorophyll. The optical absorption maximum of these compounds in organic solvents as well as in physiological media containing protein, e.g. cell culture media, is 762 nm, which is well located in the longer wavelength part of the "photodynamic window". Since these longer wavelengths penetrate deeper into the tissue, the removal of the whole malignant tissue is possible. The molar absorption coefficient of these compounds is 70,000, and thereby these compounds are more efficient than others used for PDT. Moser et al. (1995) demonstrate the photodynamic activity of the bacteriopheophorbides in cultured cancer cells (OAT 75, A 375 cells). Neither 13-OH-bacteriopheophorbide nor metallo derivatives have been applied to humans. However, they have been tested for their tumour selectivity and therapeutic effects in animals. The compounds are preferably efficient due to their low "threshold dose", low overshoot, and high photodynamic activity (photodynamic constant LD 90 = 0.5 – 1.0 J/cm²).

Since bacteriopheophorbide and its derivatives meet the special requirements for penetration through the epidermis, they are especially well suited for topical administration. The unique structure of mammalian epidermis, which is designed to protect the organism from substances of the environment, makes the penetration into the skin impossible for many drugs. The barrier function is achieved by corneocytes linked to and embedded in lipid layers. Such barrier can be penetrated only by hydrophobic substances, such as bacteriopheophorbides.

A major component of compositions for topical application is the carrier. The term "carrier" as used herein refers to carrier materials suitable for topical applications of drugs, including such materials known in the cosmetic and medical fields. Suitable carriers can be, for example, ointments, creams, or lotions. Oil-in-water emulsions,

such as cold cream bases, can also be used. The topical carriers described herein also include various agents and ingredients commonly employed in dermatological and cosmetic ointments and lotions. The more hydrophilic the carrier is, the more efficient the drug's penetration into the skin, because of better separation from the carrier cream. The photo toxic compounds can be mixed with the carrier in a solubilized form. The bacteriopheophorbides are poorly soluble in water, but well soluble in DMSO, methanol, acetone, and 2-methoxy ethanol. 2-methoxy ethanol shows no toxicity to human skin, especially when it is diluted **[with cream]** to < 20 % (w/w).

It is also preferred that a topical formulation includes a skin penetration agent. One of the commonly used skin penetration agents is DMSO, which is also a solvent for bacteriopheophorbides. Occlusion can also enhance the therapeutic effects of photo toxic dye in topical application. After the drug with the carrier is applied to the afflicted skin, a barrier is placed over the area, which prevents random passage of the topical formulation and enhances the drug's absorption into the skin.

The appropriate dosage of a photo toxic dye depends upon various factors, such as the nature of the disease, the stage of the disease, and the condition of the skin. In topical applications, the ultimate dosage delivered to the afflicted tissue depends upon factors like concentration of the photo toxic bacteriopheophorbide in the topical carrier, the amount of the topical composition which is applied to the afflicted tissue, the number of times it is applied, and the condition of the skin. In general, a concentration of 400 μM of bacteriopheophorbide in a topical composition is suitable to obtain sufficient amounts of the dye in the skin. Generally, a period of time is allowed to elapse after administration of the photo toxic dye and before exposing the afflicted tissue to radiation. The length of time necessary varies depending upon the nature of the disease, the mode of the application, and other factors. In general, a period up to about 24 hours is appropriate. This should allow sufficient time for the dye to penetrate the skin and localize in the cells of the afflicted tissue. While it may be necessary to apply the topical compositions of the present invention only once prior to radiation, it may also be necessary to repeat the application several times prior to exposure in order to obtain sufficient quantities of photo toxic dye in the afflicted tissue. To obtain complete eradication or clearing of a

particular hyperproliferative epithelial disease, it may also be necessary to repeat the entire regimen of topical or interdermal applications followed by radiation. When the diseases are chronic and treatments only relieves symptoms, e.g., psoriasis, continued maintenance therapy may be required. Because the present invention has less side effects and less cumbersome, it has the advantages over the prior arts in treating such diseases.

The irradiation is performed after infiltration of the photo toxic dye into the afflicted region of the skin. Non-damaging forms of radiation in the red region of the visible spectrum are sufficient to activate the photo toxic action of the bacteriopheophorbides. The radiation source can be sunlight or a bright lamp. For the deeper penetration into the tissue, a diode laser (762 nm emission) or a lamp equipped with a red light filter (exclusion limit < 762 nm) is more specific and suitable. Typically irradiation intensity on the surface can be up to 200 mW/cm², without causing thermal effects. Depending on tissue pigmentation different values may apply. While surface cooling may allow higher intensities, without thermal effects, another limiting factor is the oxygen supply, required for the photodynamic effect. For this reason intermittent irradiation pattern or scanning irradiation can be used with advantage. In scanning irradiation, that would be of particular advantage for treating larger surface areas, when only a limited amount of irradiation power is available, the same spot is scanned repeatedly with an appropriate spot size, say 1 cm², to allow the oxygen supply to regenerate in the interval. The irradiation must in no case be less than 4 mW/cm² at the depth of the tissue desired for the therapeutic action. Irradiation times can be typically up to 10 min, this irradiation times can also be cumulative for instance by utilizing a 1 min irradiation, and 2 min non-irradiation cycle repeated ten times in sequence. Wolbarsht, (1992) shows how to calculate the penetration depth using light absorption coefficients of skin.

The present invention is further illustrated by the following examples, but is not limited thereby.

Example 1: Preparation of an ointment as carrier with the photo toxic bacteriopheophorbide.

Basic ointment DAC is a medical carrier for hydrophobic as well as hydrophilic drugs, and allows an effective transfer of the hydrophobic bacteriopheophorbide into the skin through the hydrophobic lipid layers of the epidermis. The following composition has a final concentration of 400 μ M bacteriopheophorbide, which can be varied according to the requirements of the application.

This composition should be available by prescription under the name "Bacphein-400 ointment" in future.

Basic ointment DAC.....	80.0 G
2 mM solution of bacteriopheophorbide in 2-methoxy ethanol.....	20.0 G
sum.....	100.0 G

Example 2: Preservation of the photo toxic dye from oxidation.

The ointment as formulated in example 1 is protected from oxidation by filling the ointment into a tube wrapped by a tight closure. Under these conditions, oxidation can be prevented for at least three months.

Example 3: Application of the composition to the skin and infiltration of the photo toxic agent into the skin at certain time period that generally required between application and irradiation.

The infiltration of the dye can be observed by the fluorescence of the skin. For this purpose, the ointment is applied in ~ 1 mm thickness to the skin and removed after a time span of 2, 4, 6, 12 or 24 hours. After application, the skin is cut by a microtome transversely, and is observed under a microscope with excitation of the fluorescence of the dye using radiation with 530 nm wavelength. The diffusion depth was found to be deep enough to cover all cancerous tissue in primary melanoma and other skin diseases like psoriasis.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to these precise embodiments, and that changes and modifications may be effected therein by one skilled in the art without departing from the scope of the invention as defined in the appended claims.

What is claimed is:

1. A composition for topical application in the photodynamic therapy of an epithelial disease comprising:
a topical carrier; and
a therapeutically effective amount of a photosensitizer, wherein said photosensitizer is bacteriopheophorbide or a bacteriopheophorbide derivative.
2. A composition according to claim 1, wherein said topical carrier is selected from a group: a cream, an ointment, a gel, and a lotion.
3. A composition according to claim 1, wherein said photosensitizer is bacteriopheophorbide.
4. A composition according to claim 1, wherein said photosensitizer is bacteriopheophorbide derivatives, preferably metallo derivatives.
5. A composition according to claim 1, wherein said topical carrier comprises a skin penetration enhancing agent.
6. A composition according to claim 1, wherein said epithelial disease can be tumorous skin malignancies, melanoma and Kaposi sarcoma, psoriasis, wounds infected by gram positive bacteria, or wounds infected by gram negative bacteria.
7. A method of photo chemotherapy for hyperproliferative epithelial diseases comprising the steps of:
 - (a) applying topically a composition according to claim 1 to an area of tissue afflicted by a proliferate epithelial disease;
 - (b) waiting for a time period that is necessary for said composition to infiltrate into said tissue; and

- (c) exposing said tissue to radiation to photoactivate said photosensitizer to produce a cytotoxic response in said tissue.
8. A method of photo chemotherapy for hyperproliferative epithelial diseases comprising the steps of:
- (d) applying topically a composition according to claim 1 to an area of tissue afflicted by a proliferate epithelial disease;
 - (e) waiting for a time period that is necessary for said composition to infiltrate into said tissue; and
 - (f) removing remnants of said composition from the skin surface by wiping, washing and/or utilising suitable solvents
 - (g) exposing said tissue to radiation to photoactivate said photosensitizer to produce a cytotoxic response in said tissue.
 - (h) Applying, if necessary, a protective layer or bandage to the sensitised skin surface for a time interval corresponding to a clearance time of said photosensitizer, so as to enable the patient to be exposed to daylight or even sunlight

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/24964

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/40 US CL : 514/410 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/410 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	US 6,123,923 A (UNGER et al) 26 September 2000, see entire text, especially claims.	1-8
Y	US 5,599,831A (PORETZ et al) 04 February 1997, see full text and claims, especially column 6, lines 10-65.	1-8
Y	US 5,726,169 A (SCHERZ et al) 10 March 1998, see entire text, especially column 8, lines 13-34.	1-8
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "G" document member of the same patent family	
Date of the actual completion of the international search 21 SEPTEMBER 2001		Date of mailing of the international search report 24 OCT 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer VICKIE KIM Telephone No. (703) 305-3257

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/24964

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

CAS ONLINE, MEDLINE, BIOSIS, CANCERLIT, TOXLINE, USPATFUL, PCTFUL
search terms: bacteriopheophorbide, photodynamic, porphyrin, topical application, ointment, gel, lotion, cream,
photosensitizer, tumor, cancer